Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum at 10:00 a.m. ET on Wednesday, April 9, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/stifel99/celc/2065375; and
• A fireside chat at the 24^th Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/needham146/celc/2212811.

Alternatively, the live webcasts will be accessible from the Investors section of the company's website at

with a replay available shortly after the live events.

About Celcuity 

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR ("PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently recruiting patients. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and Twitter.

View source version of release on GlobeNewswire.com

Contacts: 

Celcuity Inc. 

Brian Sullivan, [email protected] 

Vicky Hahne, [email protected] 

(763) 392-0123 

ICR Healthcare

Patti Bank, [email protected]

(415) 513-1284